AUSTRALIAN BIOTECHNOLOGY SECTOR SNAPSHOT 2022
About AusBiotech and Grant Thornton

About AusBiotech
AusBiotech is Australia’s biotechnology industry organisation representing over 3,000 members, covering human health, medical devices and diagnostics, and agricultural biotechnology sectors. Dedicated to the development, growth and prosperity of the Australian biotechnology industry for more than 35 years, AusBiotech provides initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world.

AusBiotech is a not-for-profit organisation, with representation in each Australian state and in various special interest sectors. Active state-based committees and national advisory groups provide a network to support members and promote the commercialisation of Australian bioscience in the global marketplace.

The membership base includes biotechnology companies, ranging from start-ups to mature multinationals, research institutes and universities, specialist service professionals, corporate, institutional and individual members from Australia and overseas.

For further information or to submit any comments in relation to the Snapshot, contact:

AusBiotech
Level 3, 15 Queen Street,
Melbourne, VIC 3000
E admin@ausbiotech.org
W ausbiotech.org

About Grant Thornton
Grant Thornton Australia is a member firm of the Grant Thornton global network – one of the world’s leading independently-owned and managed accounting and consulting firms. We have the scale to meet your changing needs – while retaining the agility required to keep you one step ahead.

In Australia, we have over 1,300+ people across Sydney, Adelaide, Brisbane, Melbourne, Perth and Cairns – each with the freedom to drive change and advocate for our clients.

With our values at the core, we seek out diverse perspectives and challenge when necessary to deliver positive progress for your business. No matter your industry, business lifecycle stage, market or growth plans, our experienced professionals are dedicated to achieving the best outcome for you and your stakeholders.

Grant Thornton’s Life Sciences team help pharmaceuticals, medical devices, bio-engineering and other medical research companies to achieve real competitive advantage, now and into the future. A comprehensive range of services enables life sciences companies to secure their growth at all stages of development, from pre-clinical research to development, commercialisation and product sale.

For further information, please contact:

Michael Cunningham
National Head of Life Sciences
Grant Thornton Australia
T +61 3 8663 6007
E michael.cunningham@au.gt.com
Executive Summary

The life sciences sector in Australia works from bench to bedside, and includes industry companies (medical technologies [devices and diagnostics] and digital health, biotherapeutics, food and agriculture), research institutes, government and regulatory organisations, funding bodies and support services. The Sector Snapshot 2022 (the Snapshot) was commissioned by AusBiotech to provide both an overview of the sector in Australia, in terms of organisation and employment numbers, and to determine how the sector has changed since this data was collected in 2017 and 2019.

The report also offers critical metrics that align to AusBiotech’s Biotechnology Blueprint (Blueprint), a strategic decadal framework developed by industry, for industry. The Blueprint metrics seek to track the maturity and vibrancy growth in our ecosystem, to measure the Australian biotechnology industry’s global and local standing, and the industry’s positive contribution to Australian prosperity.

This report reveals significant sector growth of 43 per cent in the past two years, with 2,654 organisations collaborating across the country. The research also shows that 1,427 of the 2,654 organisations (54 per cent) are industry-based; the number of companies undertaking biotech research and development has grown by 40% since 2019.

The high-value talent backing our Australian biotechnology sector has increased and there are now approximately 263,693 people employed. The number of employees behind our biotech companies has also expanded, increasing 21 per cent compared to 2019 from approximately 87,397 people in 2019 to 105,569 in 2022.

The Australian life sciences industry is dominated by the medical technologies [devices and diagnostics] and digital health companies (577), followed closely by biotherapeutics companies (548) and then food and agriculture biotechnology companies (302).

In terms of the economic impact of the sector, there are currently 192 life sciences companies listed on the Australian Securities Exchange (ASX), increasing by 19 per cent from 2019’s 161 listed companies. 26 of these companies have listed in the last 24 months. Collectively ASX-listed biotech companies now represent a market capitalisation of approximately $233 Billion (compared to around $170B in 2019), demonstrating a substantive 37 per cent increase in value.

Gender equity figures remain stable with female representation very close to or over 50 per cent in funding bodies, government and regulatory organisations, and research institutions. Women in industry are still under-represented (35 per cent), however, this has increased since 2019’s Sector Snapshot survey (32 per cent). As seniority increases, female representation decreases and, overall, female representation in management level positions across the sector remains below 50 per cent.
There are 2,654 organisations in the Australian life sciences ecosystem.

More than 192 life sciences companies are listed on the ASX and represent a market capitalisation of approximately $233 Billion (~$170B in 2019).

Victoria and New South Wales are critical hubs of the life sciences sector with 73% of the sector calling them home.

There are 2,654 organisations in the Australian life sciences ecosystem.

The life sciences sector has grown by 43% since 2019 and 60% since 2017.

263,693 employees support the Australian life sciences ecosystem.

799 support service companies represents 30% of the sector (increasing 65% since 2019), it has increased 65 per cent since 2019.

Women representation in industry has increased to 35%, increasing from 32% in 2019. Overall, women represent 53% of the life sciences workforce.

Industry represents 54% of the life sciences sector, and employs 40% of the biotech workforce.

There are 1,427 companies in the life sciences industry, increasing 40% (from 1,017) since 2019.

More than 192 life sciences companies are listed on the ASX and represent a market capitalisation of approximately $233 Billion (~$170B in 2019).
The Australian Life Sciences Sector: 2,654 organisations

Australia’s Life Sciences Sector

1,427 Industry Companies

Medical technology & digital health
- Medical product
- Diagnostic device
- Software as a medical device

Biotherapeutics
- Medicines
- Vaccines
- Therapies, including cell therapies
- Consumer health

Food & agriculture
- Industrial
- Plants

32 Government & Regulatory Organisations

Regulatory
- Federal
- State

799 Support services

Accelerators & incubators

Supply & manufacturing

Accounting & financial services

Contract research organisations, including for clinical trials

230 Research Institutes

Distributors

Patient support & science communication

Consulting

Legal

Industry body & professional organisations

166 Funding Bodies

Private research institutes

Universities

Philanthropic organisations

Venture capitalists & angel investors

State and federal grants & programmes

Accelerators & incubators

Accelerators & incubators

State and federal grants & programmes

Venture capitalists & angel investors

Philanthropic organisations

State and federal grants & programmes

Accelerators & incubators
Key findings

The Australian biotechnology sector has grown by 43 per cent since 2019 and 60 per cent since 2017

There are 2,654 organisations identified as being part of the biotechnology sector, as defined by this report. This includes companies and organisations within industry, funding bodies, government and regulation, research institutes, and support services sub-sectors (Sector map, pages 7-8). The sector has seen a 43 per cent increase since this report was last published in 2019.

This has grown year-on-year since AusBiotech’s Sector Snapshot research was first commissioned: growing from 1,654 organisations in 2017, to 1,852 organisations in 2019. Over the four years, the sector has seen overall growth of 60 per cent.

The scale of the Australian life sciences industry is a key factor for the industry’s sustainability and its ability to attract and retain talent.

Of the total number of organisations, industry comprises of 1,427 companies, making up 54 per cent of the life sciences sector in Australia (Figure 1.1). This year industry saw a 40 per cent growth since 2019; while categorising is complex given technology convergence, it includes 577 medical technology and digital health companies, 548 biotherapeutics companies, and 302 food and agriculture companies.

Support services make up the second largest portion of the sector (30 per cent) with 799 organisations; this category encompasses organisations ranging from legal firms, to consultancies, to manufacturers and distributors. This sub-sector has seen significant growth of 65 per cent since last reported. While funding bodies make up just six per cent of the sector, it has seen high growth of 29 per cent in the past two years.

The life sciences workforce has increased by 8 per cent since 2019

There are approximately 263,693 people employed in the life sciences sector across the 2,654 organisations. When compared to the employee numbers reported in 2019, there has been an 8 per cent overall increase in the number of people employed by the sector (from 243,406 in 2019).

Industry capabilities have increased by 21 per cent compared to 2019, increasing from approximately 87,397 in 2019 to 105,569 in 2022.

The depth and liquidity of the life sciences job market across Australia is necessary to attract and retain people into its high-value roles, as it delivers economic and social benefits for Australia and Australians.

1 This data set includes a broad confidence interval due to large companies having a range of employee numbers (100 to ~4,000).

Critical Australian life science sector hubs

Almost three-quarters (73 per cent) of the entire life sciences sector (Figure 1.2) calls New South Wales (986 organisations; 37 per cent) and Victoria (948 organisations; 36 per cent) home, with each state growing 51 per cent and 39 per cent respectively. Queensland has seen 60 per cent growth, retaining the third largest number of life sciences organisations (324; 12 per cent). Western Australia continues to steadily grow, increasing 9 per cent from 179 in 2019 to 244 in 2022. South Australia represents 6 per cent of the sector, growing 39 percent to 135 organisations. Tasmania has shown no marked change in the size of its life sciences sector since 2017.

The highest proportion of all people employed in the life sciences sector (Figure 1.3) are based in Victoria (100,642 people) and New South Wales (89,537 people), together making up 72 per cent of the workforce. Queensland has the third-largest proportion of the life sciences workforce in Australia (32,678), demonstrating 18 per cent growth since 2019.

Industry has grown 40% since 2019, and comprises of 54% of the life sciences sector

Australian biotechnology industry growth

State-based ecosystem growth

State-based employee growth
Key findings

State-based growth by sector

State-based employee growth by sector

Figure 1.4

Figure 1.5

Figure 1.6

Figure 1.7
Key findings

State-based industry growth

![Figure 1.8](data:image/png;base64,)<br>

State-based employee growth by industry

![Figure 1.9](data:image/png;base64,)<br>

State-based industry growth

![Figure 1.11](data:image/png;base64,)
Funding and Government support for the biotech industry

In the 35 years since AusBiotech was founded as the Australian Biotechnology Association, the industry has grown from a mere handful of companies, to having an ASX-listed market capitalisation of more than $232.8 billion in 192 industry companies, and a further 1,236+ companies creating value.

The last two years have been particularly significant for the life sciences sector. The transformative power of what we have collectively experienced has shone a light on our sector’s capabilities and opportunities, and has cemented the industry’s importance in the eyes of the Australian Government and investors alike.

Pre-COVID-19 life sciences was already an economically significant industry; now the social and economic opportunities and benefits the sector provides to Australia and the world is respected even more. Australia’s mature and thriving industry is well-placed to participate in the global industry growth being experienced.

A record-high for life sciences capital raising was experienced in 2021, however, unquenched, the thirst for capital and skills remains as industry feeds its need for commercialisation, clinical development, and growth amid an expanding industry that is being driven by a flourishing digital health sector.

Capital raising

A host of listings has taken place since 2020, with 26 new biotech and medical technology companies listing on the ASX. This has resulted in the total number of life sciences companies working on commercialising Australia’s leading science, and developing and/or delivering for patients and consumers rising to 192. The number of ASX-listed biotech companies has grown significantly, with a 19 per cent increase since 2019 (161 companies), or a 37 per cent increase since 2017 (140 companies).

In line with global trends, there has also been an influx of investment and value into these companies, and the collective market capitalisation now stands at approximately AUD$232.8 billion. The market cap is one quantifiable measure of the life sciences sector’s economic contribution to the Australian economy. This has increased 37% since 2019 (approximately $170 billion).

Of the 192 companies, 13 companies (7 per cent) have a market cap of more than $1 billion, and 69 companies (36 per cent) are worth more than $100 million. The proportion of biotech companies achieving market valuations greater than $100 million measures the industry’s ability to create companies of significant future value.

Over the past 24 months, we have seen the highest level of capital raising for Australian life science companies on record. Annual data collected and reported by Bioshares shows that the capital raised by ASX-listed biotech companies in 2021 was a record high of $8 billion, of which $6.3 billion can be attributed to home-grown biotech company CSL. This capital raising builds on the $1.7 billion in 2020, and the $1.06 billion raised the year prior. The year-on-year record-breaking capital raising indicates investors’ support and recognition of the biotech industry’s future growth, as well as buoyant capital attraction globally.

Government support

At the time of writing, Australia recently elected its 31st Federal Government of Australia. While the details behind the incoming Government’s pledges are yet to be revealed, it is notable that the Australian biotechnology and life sciences sectors have enjoyed non-partisan, solid support from governments over many years, including Federal and State governments; this ongoing support will be critical as industry’s growing need for capital attraction and skills reflects its mature and vibrant ecosystem.

Governments at Commonwealth and State level have played an important role in developing the biotechnology industry, ranging from investments in R&D and support for skills development, to the framing of regulatory and tax policies that impact the sector. Even before the COVID-19 pandemic, governments identified biotechnology as a priority growth sector. This has proven to be a valuable investment, with numerous Australian companies playing a part or taking the lead in the pandemic response.

In a globally mobile industry such as biotechnology, a strong and supportive policy environment is essential to attracting new investment and intellectual capital and retaining the value that has and can be created by companies and their investment.

Therefore, the role of the incoming and future governments will be to continue existing support, particularly in enabling policy levers that enable ongoing attractiveness of the sector relative to competing markets and also to other sectors. It is critical for industry’s ongoing success in accessing and deploying investor capital that Australia and Australian companies remain competitive, and that the business operating environment is conducive to biotechnology investment.

Investment in ‘medical science’, innovation, and advanced manufacturing, as well as support to legislate the Australian Economic Accelerator as part of the University Research Commercialisation Action Plan, was announced by the Australian Labor Party during its lead-up to Election. The Party also pledged a $15 billion ‘National Reconstruction Fund’ to co-invest in Australia’s national sovereign capability, including a dedicated $1.5 billion Medical Manufacturing Fund.

AusBiotech’s Biotechnology Blueprint is a key ‘blueprint’ for industry and governments [Federal and State] to navigate the pathway ahead and deliver on our national purpose as we improve patients’ quality of life. A shared understanding and strong relationships will be key to understand each other’s needs, and in obtaining agreement and meeting Blueprint recommendations in the short and longer term, including fulfilling Australia’s ability to meet sovereignty, innovation, technology, and manufacturing goals.

1 As of March 2022, Australasian Biotechnology journal
<table>
<thead>
<tr>
<th>Company name</th>
<th>ASX</th>
<th>Listing date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nyrada INC.</td>
<td>NYR</td>
<td>January 2020</td>
</tr>
<tr>
<td>Emyria Limited</td>
<td>EMD</td>
<td>February 2020</td>
</tr>
<tr>
<td>Little Green Pharma LTD</td>
<td>LGP</td>
<td>February 2020</td>
</tr>
<tr>
<td>Atomo Diagnostics Limited</td>
<td>AT1</td>
<td>April 2020</td>
</tr>
<tr>
<td>Area Biosurgery Limited</td>
<td>ARX</td>
<td>July 2020</td>
</tr>
<tr>
<td>IDOMedical Limited</td>
<td>4DX</td>
<td>August 2020</td>
</tr>
<tr>
<td>Cleanspace Holdings Limited</td>
<td>CSX</td>
<td>October 2020</td>
</tr>
<tr>
<td>Control Ilonics Limited</td>
<td>CBL</td>
<td>December 2020</td>
</tr>
<tr>
<td>Hexima Limited</td>
<td>HRX</td>
<td>December 2020</td>
</tr>
<tr>
<td>Chimeric Therapeutics</td>
<td>CHM</td>
<td>January 2021</td>
</tr>
<tr>
<td>Truscreen</td>
<td>TRU</td>
<td>January 2021</td>
</tr>
<tr>
<td>Singular Health</td>
<td>SHG</td>
<td>February 2021</td>
</tr>
<tr>
<td>Island Pharmaceuticals</td>
<td>ILA</td>
<td>April 2021</td>
</tr>
<tr>
<td>Argenica Therapeutics</td>
<td>AGN</td>
<td>June 2021</td>
</tr>
<tr>
<td>Hitig Limited</td>
<td>HQ</td>
<td>June 2021</td>
</tr>
<tr>
<td>BCAL Diagnostics</td>
<td>BDX</td>
<td>July 2021</td>
</tr>
<tr>
<td>Lumes Diagnostics</td>
<td>LDX</td>
<td>July 2021</td>
</tr>
<tr>
<td>Clarity Pharmaceuticals</td>
<td>CU6</td>
<td>August 2021</td>
</tr>
<tr>
<td>Pacific Edge Limited</td>
<td>PEB</td>
<td>September 2021</td>
</tr>
<tr>
<td>Artrya Ltd</td>
<td>AYA</td>
<td>November 2021</td>
</tr>
<tr>
<td>Biome Australia</td>
<td>BIO</td>
<td>November 2021</td>
</tr>
<tr>
<td>EBR Systems</td>
<td>EBR</td>
<td>November 2021</td>
</tr>
<tr>
<td>Radiopharm Therapeutics Limited</td>
<td>RAD</td>
<td>November 2021</td>
</tr>
<tr>
<td>Tissue Repair LTD</td>
<td>TRP</td>
<td>November 2021</td>
</tr>
<tr>
<td>Firebrick Pharma Ltd</td>
<td>FRE</td>
<td>January 2022</td>
</tr>
<tr>
<td>Microba Life Sciences Ltd</td>
<td>MAP</td>
<td>April 2022</td>
</tr>
</tbody>
</table>

**Gender diversity in the Australian life sciences sector**

Women form 53 per cent of the workforce across the life sciences sector and this has not varied markedly since 2017 (50 per cent). Female representation in senior positions (executive, board, CEO/founder) was mostly under 50 per cent across the sector except in government and regulatory organisations and support services. However, there was an overall increase in the percentage of women in board positions and as CEO/founder roles, when compared to 2019 (Figure 2.1).

**Gender representation in positions of leadership**

**Gender representation in positions of leadership in industry**
### Appendix A – Definition List

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Life sciences sector</td>
<td>As defined by the scope of the project, this includes all entities involved in sciences that have a direct or indirect impact on human life. This does not include animal sciences (i.e., companion animals and sporting animals), but includes organisations involved in veterinary pharmaceuticals.</td>
<td>This definition includes all businesses, governments, research institutes, and all individuals employed that support the growing life sciences industry in sciences relating directly or indirectly to human life, including those used in the primary industries but not in sporting and companion animal life sciences. This sector is broken down into digital health, food &amp; agriculture, biotechnology, medicinal research institutes, funding bodies, support services, and government &amp; regulatory.</td>
</tr>
<tr>
<td>Food &amp; agriculture</td>
<td>This category includes all organisations that develop and sell technological innovations that improves, or create new processes for food, agricultural, or environmental purposes. These innovations are in the life sciences sector.</td>
<td>This has been divided from the Department of Industry definition. This sector is broken down into research and companies.</td>
</tr>
<tr>
<td>Medical technology &amp; digital health</td>
<td>Medical technology includes a wide range of medical devices (including in vitro diagnostic) used for diagnosis, treatment, or disease management; medical software (including AI for healthcare), clinical data analytics and software. Digital health includes software that works to allow patients to manage their health (wearables or mobile data collection) that can capture data about patient treatments and non-drug factors.</td>
<td>The definition for medical technology is obtained from the Australian Medical Association. This category is broken down into companies, research, and clinical services. The definition for digital health is a combination of the Nature and EU definition of digital health. This category is broken down into unregulated applications and software, as well as the regulated.</td>
</tr>
<tr>
<td>Biopharmaceuticals</td>
<td>This is defined as the industry concerned with the discovery, research, development, regulation and commercialisation of human and veterinary pharmaceuticals.</td>
<td>This is the general definition for the industry including all cellular and regenerative therapeutic medicines.</td>
</tr>
<tr>
<td>Government &amp; regulatory</td>
<td>This is defined as the bodies that govern businesses, research institutes and workers within the life sciences sector. The sector answers to, or is formed by key policies, regulations, funding, laws, and governance. Entrepreneur and government &amp; regulatory bodies such as the Therapeutic Goods Administration (TGA) for therapeutic medicine and technology and digital health technology; Food Standards Australia New Zealand (FSANZ); for food biotechnology; GMP; for pharmaceuticals; Australian Technology and Standards Authority (ATSA); for animal identification and veterinary products; or animal medicines, and agricultural chemicals. Furthermore, the sector is supported by several federal and state government departments that specifically fund and govern the sector such as Australian government.</td>
<td>Information from government websites, including: Government website.</td>
</tr>
<tr>
<td>Funding bodies</td>
<td>This category is defined by organized entities that provide, invest in research, business development and commercialization of life sciences companies and/or organizations.</td>
<td>The definition should include any entity (business or organisation) that invests large amounts of money in companies in return for a stake in the company or equity, but does not include stakeholders or external shareholders. This also includes business insurances and accelerators that operate in the life sciences industry.</td>
</tr>
<tr>
<td>Support services</td>
<td>This category is defined as all organisations that provide support to life sciences companies and/or organizations.</td>
<td>This sector should include any company or entity that supports the sector, including: management firms, contract research organisations (CROs), contract manufacturing organisations (CMOs), and distributors.</td>
</tr>
<tr>
<td>Research institute</td>
<td>This is defined by organisations that are part of research in life sciences, either privately or publicly.</td>
<td>Universities and private research institutions will be included.</td>
</tr>
<tr>
<td>Life sciences employee</td>
<td>A person employed (for tax purposes) within Australia for a life sciences company/organisation/government organisation that operates in Australia.</td>
<td>The data was collected in Australia that supports the sector and pays Australian taxes.</td>
</tr>
<tr>
<td>Current</td>
<td>Data collection for this report occurred between July and September 2021.</td>
<td>The most current and reliable available sources were used for data collection, including government websites, company websites, peer-reviewed websites, databases, and industry information.</td>
</tr>
<tr>
<td>Company size</td>
<td>Defined by the number of employees, where a small company has less than 20 employees, a medium company has less than 100 employees, and a large company has over 100 employees.</td>
<td>This follows the AusBiotech definition of company sizes.</td>
</tr>
</tbody>
</table>

### Appendix B – Methods & Statistics

**Overview**

The comprehensive list of 2,693 organisations obtained in 2022 was verified using various public websites and databases. Companies with non-visible, those which were acquired, insolvent, irrelevant, or without products/patents were removed. New companies were identified using the MedTech member list and sector databases in combination with the databases referred to previously and stakeholder engagement. Of the resulting list of 2,684 organisations, 1,210 medium organisations were further probed to determine that employee numbers along with the percentage of employees that work in the life sciences sector gender distribution as well as whether they were public or private organisation. The percentage of staff involved in life sciences in each category was determined based on company/governmental background.

The assumptions made for the proportion of staff directly involved in the life sciences sector are as below:

- In large universities (over 35,000 students) 15 per cent of the staff were assumed to be involved in the life sciences, whereas in smaller universities (less than 35,000 students) 10 per cent of the staff were assumed to work in life sciences.
- 10 per cent of hospital staff are estimated to be involved in the life sciences sector. In this category, researchers including physicians that are involved in clinical trials.
- For organisations that have less than 30 employees, it was assumed that 20 per cent of the employees are involved in the sector as smaller organisations usually have employees that perform overlapping functions.

These percentages were used to determine the total number of employees directly involved in the life sciences in each organisation.

**Total number of employees in a percentage involved in life sciences = total number of life sciences employees**

The size of each organisation was determined based on the total number of employees, according to the proportion of small, medium and large organisations in the sector that was determined. This information was used to extrapolate the total number of employees in the life sciences sector.

**Detailed methodology**

A refined list of 2,684 life sciences organisations was randomised and the information on 1,120 companies/organisations was obtained. Of this, complete employee numbers were obtained for 1,052 companies/organisations. These numbers were multiplied by the per centage of employees in each organisation that were involved in life sciences to obtain the number of employees that own in life sciences in each organisation/company.

**Number of life sciences employees = total employee numbers percentage of the employees involved in life sciences**

For the 1,120 life sciences companies/organisations that were stratified by sub-sector and then grouped into small, medium and large organisations based on the total number of employees. The average number of employees and standard deviation (SD) for each group was also obtained using standard Microsoft Excel functions.
Acknowledgements

This report was commissioned by AusBiotech, and data collection and analysis were carried out by Master of Biotechnology students at the University of Melbourne. Sincere appreciation is extended to all group members of the project.

Lorraine Chiroiu  
CEO, AusBiotech

Karen Parr  
Director, Communications & Policy

Mia Friedman  
MBiotech Student, University of Melbourne

Matias Policani  
MBiotech Student, University of Melbourne

Margi Mungalpara  
MBiotech Student, University of Melbourne

David Rogers  
Manager, Careers and Industry, University of Melbourne

Caitlyn Wiltshire  
MBiotech Student, University of Melbourne

Associate Professor Graham Hepworth  
School of Mathematics and Statistics, University of Melbourne

Disclaimer

This report provides a statistically quantified snapshot of the employment numbers as well as the sector, state and gender distribution within the Australian life sciences sector. The information presented within this report has been derived from data that was collected over a six-month period from July to September 2021. It should be noted that the employee numbers presented are approximations based on statistical calculations and should not be taken as definitive.

The material in this publication is intended to provide a general summary only and should not be relied on as a substitute for legal or other professional advice. You should obtain your own legal or other professional advice. Whilst every care has been taken in producing this information, no warranty is given or implied as to the accuracy. To the extent permitted by the law, no responsibility for any loss [whether in negligence or otherwise] occasioned by anyone acting or refraining from acting as a result of this information is accepted by AusBiotech. © May 2022

Grant Thornton Australia Ltd ABN 41 127 556 389 ACN 127 556 389 ‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.